{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:49:42Z","timestamp":1792014582259,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103216","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:35:56Z","timestamp":1790033756000},"page":"103216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel"],"prefix":"10.1016","volume":"150","author":[{"given":"Francesco","family":"Mattana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Palesandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Dragonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2026.103216_bb0005","article-title":"Cancer statistics, 2026: charting a course for a national cancer research agenda","volume":"76","author":"Lara","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103216_bb0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2026.103216_bb0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.109","article-title":"Survival outcomes based on line of therapy and treatment trends with cabazitaxel in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","author":"Jo","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9747","key":"10.1016\/j.ctrv.2026.103216_bb0020","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.ctrv.2026.103216_bb0025","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of Cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in Postdocetaxel patients with metastatic castration-resistant prostate Cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103216_bb0035","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103216_bb0045","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.ctrv.2026.103216_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bju.14876","article-title":"TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial protocol ANZUP 1603)","volume":"124","author":"ANZUP TheraP team","year":"2019","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103216_bb0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2967\/jnumed.124.268807","article-title":"Real-world comparison of Cabazitaxel versus 177Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate Cancer","volume":"66","author":"Wenzel","year":"2025","journal-title":"J Nucl Med"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103216_bb0060","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1200\/JCO.2025.43.16_suppl.5076","article-title":"Comparative effectiveness of cabazitaxel (C) vs. lutetium Lu-177 vipivotide tetraxetan (Lu) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Ozay","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103216_bb0065","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-025-04804-8","article-title":"177Lu-vipivotide tetraxetan (PSMA-617) vs cabazitaxel in metastatic castration-resistant prostate cancer: a real-world analysis using the TriNetX database","author":"Aijaz","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ctrv.2026.103216_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115789","article-title":"177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: real-world efficacy and safety data from the ARON-3 study","volume":"229","author":"Mandel","year":"2025","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103216_bb0075","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12094-018-1928-y","article-title":"Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer","volume":"21","author":"Anido-Herranz","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103216_bb0080","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103216_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123095","article-title":"Renal safety of [177Lu]Lu-PSMA-617 radioligand therapy in patients with compromised baseline kidney function","volume":"13","author":"Rosar","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103216_bb0090","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00259-024-07006-z","article-title":"Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia","volume":"52","author":"Bastian","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103216_bb0095","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","article-title":"Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with phase 3 VISION data","volume":"65","author":"Murthy","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103216_bb0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103216_bb0105","series-title":"Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)","year":"2025"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103216_bb0110","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103216_bb0115","article-title":"Association of prior PARP inhibitor exposure with clinical outcomes after 177Lu-PSMA-617 in men with castration-resistant prostate cancer and mutations in DNA homologous recombination repair genes","author":"Raychaudhuri","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103216_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e17099","article-title":"Impact of genomic alterations on outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Lu-177 radioligand therapy (RLT)","volume":"43","author":"Chalker","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103216_bb0125","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2967\/jnumed.125.269584","article-title":"[68Ga]Ga-PSMA-11 PET tumor volume predicts overall survival of patients with metastatic prostate Cancer undergoing Taxane-based chemotherapy","volume":"66","author":"Beintner-Skawran","year":"2025","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103216_bb0130","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103216_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.euo.2023.01.014","article-title":"Metastatic sites\u2019 location and impact on patient management after the introduction of prostate-specific membrane antigen positron emission tomography in newly diagnosed and biochemically recurrent prostate Cancer: a critical review","volume":"6","author":"Mattana","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103216_bb0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.semradonc.2025.05.004","article-title":"PSMA-PET guided radiotherapy in prostate Cancer: a critical review of current applications and future directions","volume":"35","author":"Dragonetti","year":"2025","journal-title":"Semin Radiat Oncol"},{"issue":"10459","key":"10.1016\/j.ctrv.2026.103216_bb0145","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103216_bb0150","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2308","article-title":"LBA65 efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)","volume":"35","author":"Sartor","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103216_bb0155","author":"Curium US LLC"},{"key":"10.1016\/j.ctrv.2026.103216_bb0160","series-title":"Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a statistically significant and clinically meaningful benefit for patients with PSMA-positive metastatic castration resistant prostate Cancer","author":"Baucells","year":"2024"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103216_bb0165","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103216_bb0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2967\/jnumed.124.268340","article-title":"Exploring the flare phenomenon in patients with castration-resistant prostate cancer: enzalutamide-induced PSMA upregulation observed on PSMA PET","volume":"66","author":"Gaag","year":"2025","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103216_bb0175","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-025-07317-9","article-title":"Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany","volume":"52","author":"Brinkmann","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103216_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132247","article-title":"Is [177Lu]Lu-PSMA-617 redefining value in mCRPC care? A Meta-analysis of clinical and economic endpoints","volume":"17","author":"Fiorica","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2026.103216_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102862","article-title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","volume":"77","author":"Herrmann","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103216_bb0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate Cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103216_bb0195","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103216_bb0200","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2967\/jnumed.123.265952","article-title":"SNMMI consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radionuclide therapy","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103216_bb0205","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2967\/jnumed.125.271077","article-title":"Quantifying the renal impact of [177Lu]Lu-PSMA-617: a longitudinal analysis of real-world data from the LUMEN registry","volume":"67","author":"B\u00fcttner","year":"2026","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103216_bb0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103216_bb0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:12Z","timestamp":1792012332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"alternative-id":["S0305737226001301"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103216","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103216"}}